Citius Pharmaceuticals, Inc. NASDAQ:CTXR

Citius Pharmaceuticals stock price today

$1.29
-2.39
-64.95%
Financial Health
0
1
2
3
4
5
6
7
8
9

Citius Pharmaceuticals stock price monthly change

+401.43%
month

Citius Pharmaceuticals stock price quarterly change

+401.43%
quarter

Citius Pharmaceuticals stock price yearly change

+366.30%
year

Citius Pharmaceuticals key metrics

Market Cap
20.74M
Enterprise value
N/A
P/E
-6.95
EV/Sales
N/A
EV/EBITDA
1.32
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
-0.24
Revenue
N/A
EBITDA
-40.25M
Income
-37.49M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Citius Pharmaceuticals stock price history

Citius Pharmaceuticals stock forecast

Citius Pharmaceuticals financial statements

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Profit margin
Mar 2023 0 -10.52M
Jun 2023 0 -8.47M
Sep 2023 0 -9.94M
Mar 2024 0 -8.54M
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Analyst Estimates
Sep 2025 12.39M 0
Oct 2025 12.39M 0
Dec 2025 46.00M 0
Mar 2026 48.00M 0
  • Analysts Price target

  • Financials & Ratios estimates

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Earnings per share (EPS)
2024-08-12 -0.05 -0.06
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Debt to assets
Mar 2023 104240826 12.43M 11.93%
Jun 2023 110404835 12.10M 10.96%
Sep 2023 103611150 12.17M 11.76%
Mar 2024 90711369 10.74M 11.84%
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Cash Flow
Mar 2023 -7.85M 0 31.26K
Jun 2023 -9.58M 0 13.79M
Sep 2023 -6.80M 0 -687
Mar 2024 -7.78M 0 0

Citius Pharmaceuticals alternative data

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Employee count
Aug 2023 21
Sep 2023 21
Oct 2023 21
Nov 2023 21
Dec 2023 21
Jan 2024 21
Feb 2024 22
Mar 2024 22
Apr 2024 22
May 2024 22
Jun 2024 22
Jul 2024 22

Citius Pharmaceuticals other data

3.00% -6.75%
of CTXR is owned by hedge funds
4.38M -9.86M
shares is hold by hedge funds

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Insider trades (number of shares)
Period Buy Sel
Apr 2019 2588996 0
Sep 2019 5586594 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
HOLUBIAK MYRON Z director, 10 perc.. Common Stock 558,597 $1.15 $642,387
Purchase
HOLUBIAK MYRON Z director, 10 perc.. Warrant to Purchase Common Stock 558,597 $1.15 $642,387
Purchase
MAZUR LEONARD L director, 10 perc.. Warrant to Purchase Common Stock 2,234,700 $3.45 $7,709,715
Purchase
MAZUR LEONARD L director, 10 perc.. Common Stock 2,234,700 $3.45 $7,709,715
Purchase
HOLUBIAK MYRON Z director, 10 perc.. Common Stock 129,450 $1.15 $148,868
Purchase
HOLUBIAK MYRON Z director, 10 perc.. Warrant to Purchase Common Stock 129,450 $1.15 $148,868
Purchase
MAZUR LEONARD L director, 10 perc.. Warrant to Purchase Common Stock 1,165,048 $3.45 $4,019,416
Purchase
MAZUR LEONARD L director, 10 perc.. Common Stock 1,165,048 $3.45 $4,019,416
Purchase
MAZUR LEONARD L director, 10 perc.. Common Stock 3,137,255 $3.45 $10,823,530
Purchase
HOLUBIAK MYRON Z director, 10 perc.. Common Stock 784,314 $1.15 $901,961
Friday, 27 December 2024
prnewswire.com
Monday, 25 November 2024
prnewswire.com
Friday, 22 November 2024
prnewswire.com
Monday, 18 November 2024
prnewswire.com
Friday, 15 November 2024
prnewswire.com
Monday, 11 November 2024
prnewswire.com
Thursday, 5 September 2024
prnewswire.com
prnewswire.com
Monday, 12 August 2024
prnewswire.com
prnewswire.com
prnewswire.com
Thursday, 8 August 2024
prnewswire.com
Monday, 5 August 2024
prnewswire.com
Thursday, 18 July 2024
newsfilecorp.com
Wednesday, 17 July 2024
newsfilecorp.com
Thursday, 11 July 2024
newsfilecorp.com
newsfilecorp.com
Wednesday, 10 July 2024
prnewswire.com
Wednesday, 29 May 2024
prnewswire.com
Tuesday, 21 May 2024
investorplace.com
prnewswire.com
Tuesday, 14 May 2024
InvestorPlace
Friday, 10 May 2024
PRNewsWire
Friday, 23 February 2024
PRNewsWire
Monday, 18 September 2023
PRNewsWire
Wednesday, 6 September 2023
PRNewsWire
Friday, 2 June 2023
Seeking Alpha
Wednesday, 11 January 2023
PRNewsWire
Wednesday, 28 December 2022
Zacks Investment Research
Tuesday, 8 November 2022
Seeking Alpha
  • What's the price of Citius Pharmaceuticals stock today?

    One share of Citius Pharmaceuticals stock can currently be purchased for approximately $1.29.

  • When is Citius Pharmaceuticals's next earnings date?

    Citius Pharmaceuticals, Inc. is estimated to report earnings on Monday, 11 Aug 2025.

  • Does Citius Pharmaceuticals pay dividends?

    No, Citius Pharmaceuticals does not pay dividends.

  • How much money does Citius Pharmaceuticals make?

    Citius Pharmaceuticals has a market capitalization of 20.74M. Citius Pharmaceuticals made a loss 39.43M US dollars in net income (profit) last year or -$0.06 on an earnings per share basis.

  • What is Citius Pharmaceuticals's stock symbol?

    Citius Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "CTXR".

  • What is Citius Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Citius Pharmaceuticals?

    Shares of Citius Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Citius Pharmaceuticals's key executives?

    Citius Pharmaceuticals's management team includes the following people:

    • Mr. Myron Z. Holubiak Pres, Chief Executive Officer & Director(age: 78, pay: $1,480,000)
    • Mr. Leonard L. Mazur Executive Chairman & Sec.(age: 80, pay: $592,920)
    • Dr. Myron S. Czuczman M.D. Executive Vice President & Chief Medical Officer(age: 66, pay: $549,670)
    • Mr. Jaime Bartushak Chief Financial Officer & Chief Accounting Officer(age: 57, pay: $500,930)
  • How many employees does Citius Pharmaceuticals have?

    As Jul 2024, Citius Pharmaceuticals employs 22 workers.

  • When Citius Pharmaceuticals went public?

    Citius Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 2 Oct 2014.

  • What is Citius Pharmaceuticals's official website?

    The official website for Citius Pharmaceuticals is citiuspharma.com.

  • Where are Citius Pharmaceuticals's headquarters?

    Citius Pharmaceuticals is headquartered at 11 Commerce Drive, Cranford, NJ.

  • How can i contact Citius Pharmaceuticals?

    Citius Pharmaceuticals's mailing address is 11 Commerce Drive, Cranford, NJ and company can be reached via phone at +90 89676677.

Citius Pharmaceuticals company profile:

Citius Pharmaceuticals, Inc.

citiuspharma.com
Exchange:

NASDAQ

Full time employees:

22

Industry:

Biotechnology

Sector:

Healthcare

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

11 Commerce Drive
Cranford, NJ 07016

CIK: 0001506251
ISIN: US17322U2078
CUSIP: 17322U207